Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology
Lillys position is that the Courts prior case-management rulings narrowed only Issue 3 , which concerns general causation, and did not similarly restrict the scope of Issue 2
Published in The BMJ on Thursday, the analysis, drawing on 262 trials covering nearly 100,000 patients, has, for the first time, ranked GLP-1 weight-loss drugs not just on kilos lost, but on survival, heart risk, kidney health and quality of life
Market and Compliance Considerations Despite the affordability gains, uncertainty remains
Medication Auto-Replenishment: Select to have HealthFirst track your expiration date and send replenishment before expiration